• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

    5.080 -0.150 (-2.87%)
    Streaming Delayed Price Updated: 11:04 AM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 105,004
    Open 5.260
    Bid (Size) 5.050 (300)
    Ask (Size) 5.110 (500)
    Prev. Close 5.230
    Today's Range 5.020 - 5.331
    52wk Range 1.340 - 7.730
    Shares Outstanding 33,577,873
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗
    Market-based odds now show an 87% chance of a rate cut. 
    Via Stocktwits
    Topics ETFs Economy Government

    Performance

    YTD
    N/A
    N/A
    1 Month
    +28.0%
    +28.0%
    3 Month
    +141.9%
    +141.9%
    6 Month
    +99.2%
    +99.2%
    1 Year
    +130.9%
    +130.9%

    More News

    Read More
    News headline image
    Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces Other Serious Diseases Strategy
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Attends FDA CEO Forum in Washington DC
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    News headline image
    On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Immix Biopharma, Inc. - Common Stock publicly traded?
    Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.
    What exchange does Immix Biopharma, Inc. - Common Stock trade on?
    Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?
    The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market
    What is the current price of Immix Biopharma, Inc. - Common Stock?
    The current price of Immix Biopharma, Inc. - Common Stock is 5.080
    When was Immix Biopharma, Inc. - Common Stock last traded?
    The last trade of Immix Biopharma, Inc. - Common Stock was at 01/02/26 11:04 AM ET
    What is the market capitalization of Immix Biopharma, Inc. - Common Stock?
    The market capitalization of Immix Biopharma, Inc. - Common Stock is 170.58M
    How many shares of Immix Biopharma, Inc. - Common Stock are outstanding?
    Immix Biopharma, Inc. - Common Stock has 171M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.